Purchase Order HHSN269201800302P

<p>The NIH Clinical Center awarded a purchase order to Illumina, Inc., valued at $6,418.66, on March 6, 2018. The order was de-obligated on March 16, 2018. Work is performed in Bethesda, Maryland. The purchase order is firm fixed price with no set-aside designation and procures Illumina's genetic sequencing and genomic analysis products or services in support of the NIH Clinical Center's research operations.</p>

The National Institutes of Health Clinical Center awarded a purchase order to Illumina, Inc. for $20,298.00 on July 20, 2018, with an ultimate completion date of August 1, 2018. No set-aside was used. Performance occurs in Bethesda, Maryland. The order procures sequencing instruments, reagents, consumables, or bioinformatics software—Illumina's core product lines for DNA and RNA analysis supporting NIH research and diagnostic operations. The firm fixed price purchase order represents a...

<p>The National Institutes of Health Clinical Center awarded a purchase order to Illumina, Inc. for $75,560.00 on March 27, 2018, with ultimate completion on April 28, 2019. Place of performance is Bethesda, Maryland. The order calls for DNA and RNA sequencing instruments, reagents, consumables, or bioinformatics software under firm fixed price. No set-aside was used.</p>

The National Institutes of Health Clinical Center awarded a purchase order to Illumina, Inc. for $22,445.10 on June 12, 2019, with an ultimate completion date of September 27, 2019. No set-aside was used. Place of performance is Bethesda, Maryland. The purchase order is firm fixed price for commercial sequencing reagents, consumables, or related biotechnology products consistent with Illumina's core federal portfolio in analytical laboratory instrumentation and in vitro diagnostic substances.

<p>The NIH Clinical Center awarded a purchase order to Illumina, Inc. for $21,636.00 on May 28, 2019, with ultimate completion on June 28, 2019. Work is performed in Bethesda, Maryland. The order covers sequencing reagents, consumables, or related bioinformatics supplies supporting the Clinical Center's genomic research and diagnostic capability. No set-aside applied.</p>

<p>The NIH Clinical Center awarded a purchase order to Illumina, Inc. for $19,112.76 on July 17, 2019, with an ultimate completion date of October 31, 2019. The order is a firm fixed price procurement with no set-aside. Work is performed in San Diego, California. The purchase order covers sequencing instruments, reagents, consumables, or bioinformatics software—Illumina's core product portfolio serving federal research and diagnostic agencies.</p>

<p>The National Institutes of Health Clinical Center awarded a purchase order to Illumina Inc. for $5,883.78 on November 28, 2017, with completion targeted for December 19, 2017. Performance takes place in Bethesda, Maryland. The order covers sequencing reagents, consumables, or related biotechnology products under firm fixed price terms. No set-aside applied.</p>

<p>The NIH Clinical Center awarded a purchase order to Illumina, Inc., valued at $112,216.00, on May 30, 2018, for an ultimate completion date of August 30, 2018. No set-aside was used. Work is performed in Bethesda, Maryland. The order procures Illumina sequencing instruments, reagents, consumables, or bioinformatics software—standard elements of Illumina's federal portfolio—under firm fixed pricing.</p>

<p>The NIH Clinical Center awarded a purchase order to Illumina, Inc. valued at $13,250.00 on January 14, 2020, for firm fixed-price delivery by January 10, 2021. Place of performance is Bethesda, Maryland. No set-aside was applied. The order procures genetic sequencing reagents, consumables, or related laboratory materials supporting genomic research activities at the Clinical Center.</p>

<p>The National Institutes of Health Clinical Center awarded a purchase order to Illumina, Inc., valued at $9,008.64, on September 22, 2017, for firm fixed price acquisition of sequencing reagents and consumables. Place of performance is Bethesda, Maryland. The order is scheduled for ultimate completion on September 21, 2018. No set-aside was used.</p>